Medela Lotus

active

 PT Medela Potentia (“Medela” or the “Company”, https://www.medela-potentia.com/en) is one of the largest healthcare and pharmaceutical distribution companies in Indonesia. Medela was established in the 1980s as the distribution arm of PT Dexa Medica (Dexa).The Company has four main business activities: (i) distribution (pharmaceuticals, health products, and medical devices) through Anugrah Argon Medica (AAM) in Indonesia and Dynamic Argon Co in Cambodia; (ii) marketing for pharmaceuticals and medical devices through Djembatan Dua (DD); (iii) digital healthcare platforms through Karsa Inti Tuju Askara (KITA); and (iv) medical consumables manufacturing via Deca Metric Medica (DMM).Medela’s distribution networks include two National Distribution Centers (NDC), 35 branches, 35 retail warehouses (mainly in conjunction with each branch office) and 3 representative sales office across different islands in Indonesia with around 75,000 sqm storage capacity in total. The company has three branches, one NDC, and two retail warehouses in Cambodia with around 1,800 sqm storage capacity.The company has a manufacturing facility inaugurated in December 2023 (around 6,000 sqm) located in Jababeka Industrial Estate, Bekasi regency, to produce medical consumables such as wound care and surgical supplies (e.g. wide area fixation, post operative dressings, advanced wound care, surgical instrument cleaning and disinfection). The company rents about 250 motorcycles and 150 vans for delivery services to pharmacies or hospitals around each branch office.The proposed investment is up to IDR520 billion (approximately US$35 million equivalent) as a lead investor in the initial public offering (IPO) of Medela (the Project). Proceeds will be used to (i) expand and modernize Medela’s distribution network by adding new storage areas, upgrading warehouse infrastructure or by relocation, including its network in the less developed region in east Indonesia, (ii) expand the medical device business segment, including the expansion of its medical consumables manufacturing facility (about 14,000 sqm), expected to be completed in fiscal year (FY) 2027 (iii) develop Medela’s digital ecosystem infrastructure and application, and (iv) expand domestically and regionally through merger and acquisition.